IDH1 mutations in oligodendroglial tumors

Comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR

Dakeun Lee, Yeon Lim Suh, So Young Kang, Tae In Park, Ji Yun Jeong, SeHoon Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Mutations in isocitrate dehydrogenase 1 (IDH1) are found in a high proportion of glial tumors and have a significant prognostic impact. Although direct sequencing has been considered to be the gold-standard method to detect this mutation, the sensitivity of this technique has been questioned especially because specimens from glial tumors may contain large numbers of non-tumor cells. We screened 141 cases of oligodendroglial tumors for IDH1 mutations using peptide nucleic acid (PNA)-mediated clamping polymerase chain reaction (PCR) and compared the results with the results of direct sequencing, pyrosequencing, and immunohistochemistry (IHC). Nested PCR was only performed in cases having mutant IDH1 only discovered by clamping PCR. Using dilution experiments mixing IDH1 wild-type and mutant DNA samples, clamping PCR detected mutations in samples with a 1% tumor DNA composition. Using PNA clamping PCR, we detected 138 of 141 (97.9%) cases with mutant IDH1 in our series, which is significantly higher (P = 0.016; PNA clamping vs. direct sequencing) than those of direct sequencing (74.5%), pyrosequencing (75.2%) and IHC (75.9%). From our results, almost all oligodendroglial tumors have IDH1 mutations, and this suggests that IDH1 mutation is an early and common event especially in the development of oligodendroglial tumors.

Original languageEnglish
Pages (from-to)285-293
Number of pages9
JournalBrain Pathology
Volume23
Issue number3
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Peptide Nucleic Acids
Isocitrate Dehydrogenase
Constriction
Immunohistochemistry
Polymerase Chain Reaction
Mutation
Neoplasms
Neuroglia
DNA
Gold

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

@article{679caac54cf04b749d7caab8b342a2f8,
title = "IDH1 mutations in oligodendroglial tumors: Comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR",
abstract = "Mutations in isocitrate dehydrogenase 1 (IDH1) are found in a high proportion of glial tumors and have a significant prognostic impact. Although direct sequencing has been considered to be the gold-standard method to detect this mutation, the sensitivity of this technique has been questioned especially because specimens from glial tumors may contain large numbers of non-tumor cells. We screened 141 cases of oligodendroglial tumors for IDH1 mutations using peptide nucleic acid (PNA)-mediated clamping polymerase chain reaction (PCR) and compared the results with the results of direct sequencing, pyrosequencing, and immunohistochemistry (IHC). Nested PCR was only performed in cases having mutant IDH1 only discovered by clamping PCR. Using dilution experiments mixing IDH1 wild-type and mutant DNA samples, clamping PCR detected mutations in samples with a 1{\%} tumor DNA composition. Using PNA clamping PCR, we detected 138 of 141 (97.9{\%}) cases with mutant IDH1 in our series, which is significantly higher (P = 0.016; PNA clamping vs. direct sequencing) than those of direct sequencing (74.5{\%}), pyrosequencing (75.2{\%}) and IHC (75.9{\%}). From our results, almost all oligodendroglial tumors have IDH1 mutations, and this suggests that IDH1 mutation is an early and common event especially in the development of oligodendroglial tumors.",
author = "Dakeun Lee and Suh, {Yeon Lim} and Kang, {So Young} and Park, {Tae In} and Jeong, {Ji Yun} and SeHoon Kim",
year = "2013",
month = "5",
day = "1",
doi = "10.1111/bpa.12000",
language = "English",
volume = "23",
pages = "285--293",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "3",

}

IDH1 mutations in oligodendroglial tumors : Comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR. / Lee, Dakeun; Suh, Yeon Lim; Kang, So Young; Park, Tae In; Jeong, Ji Yun; Kim, SeHoon.

In: Brain Pathology, Vol. 23, No. 3, 01.05.2013, p. 285-293.

Research output: Contribution to journalArticle

TY - JOUR

T1 - IDH1 mutations in oligodendroglial tumors

T2 - Comparative analysis of direct sequencing, pyrosequencing, immunohistochemistry, nested PCR and PNA-mediated clamping PCR

AU - Lee, Dakeun

AU - Suh, Yeon Lim

AU - Kang, So Young

AU - Park, Tae In

AU - Jeong, Ji Yun

AU - Kim, SeHoon

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Mutations in isocitrate dehydrogenase 1 (IDH1) are found in a high proportion of glial tumors and have a significant prognostic impact. Although direct sequencing has been considered to be the gold-standard method to detect this mutation, the sensitivity of this technique has been questioned especially because specimens from glial tumors may contain large numbers of non-tumor cells. We screened 141 cases of oligodendroglial tumors for IDH1 mutations using peptide nucleic acid (PNA)-mediated clamping polymerase chain reaction (PCR) and compared the results with the results of direct sequencing, pyrosequencing, and immunohistochemistry (IHC). Nested PCR was only performed in cases having mutant IDH1 only discovered by clamping PCR. Using dilution experiments mixing IDH1 wild-type and mutant DNA samples, clamping PCR detected mutations in samples with a 1% tumor DNA composition. Using PNA clamping PCR, we detected 138 of 141 (97.9%) cases with mutant IDH1 in our series, which is significantly higher (P = 0.016; PNA clamping vs. direct sequencing) than those of direct sequencing (74.5%), pyrosequencing (75.2%) and IHC (75.9%). From our results, almost all oligodendroglial tumors have IDH1 mutations, and this suggests that IDH1 mutation is an early and common event especially in the development of oligodendroglial tumors.

AB - Mutations in isocitrate dehydrogenase 1 (IDH1) are found in a high proportion of glial tumors and have a significant prognostic impact. Although direct sequencing has been considered to be the gold-standard method to detect this mutation, the sensitivity of this technique has been questioned especially because specimens from glial tumors may contain large numbers of non-tumor cells. We screened 141 cases of oligodendroglial tumors for IDH1 mutations using peptide nucleic acid (PNA)-mediated clamping polymerase chain reaction (PCR) and compared the results with the results of direct sequencing, pyrosequencing, and immunohistochemistry (IHC). Nested PCR was only performed in cases having mutant IDH1 only discovered by clamping PCR. Using dilution experiments mixing IDH1 wild-type and mutant DNA samples, clamping PCR detected mutations in samples with a 1% tumor DNA composition. Using PNA clamping PCR, we detected 138 of 141 (97.9%) cases with mutant IDH1 in our series, which is significantly higher (P = 0.016; PNA clamping vs. direct sequencing) than those of direct sequencing (74.5%), pyrosequencing (75.2%) and IHC (75.9%). From our results, almost all oligodendroglial tumors have IDH1 mutations, and this suggests that IDH1 mutation is an early and common event especially in the development of oligodendroglial tumors.

UR - http://www.scopus.com/inward/record.url?scp=84876283937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876283937&partnerID=8YFLogxK

U2 - 10.1111/bpa.12000

DO - 10.1111/bpa.12000

M3 - Article

VL - 23

SP - 285

EP - 293

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 3

ER -